The 2017 News Archive of Autifony Therapeutics: researching treatments for hearing disorders – tinnitus & age related hearing loss - & schizophrenia

2017 News Archive

Autifony Therapeutics obtains £1.3 million in funding from Innovate UK and the Dementia Discovery Fund to explore novel approach to treatment of dementia

London, UK -  15 March 2017 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced a new funding award of £895,000 from the Biomedical Catalyst for initiation of a research programme with a novel approach to the treatment of dementia. An investment of £400,000 from the Dementia Discovery Fund (“DDF”) will also be used to pursue this highly novel approach to dementia treatment.

Read more


Autifony Therapeutics announces positive results from Phase I study of AUT00206, a first-in-class Kv3 modulator for treatment of schizophrenia

London, UK -  10 January 2017 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced positive findings from a Phase Ia clinical trial of AUT00206, a first-in-class Kv3 modulator in development for the treatment of schizophrenia, as well as the start of the first of two Phase Ib studies with the molecule.

Read more